FDA
-
-
-
-
-
-
-
FDA approves Omeros' YARTEMLEA for stem cell transplant complication
-
-
-
-
-
-
-
Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group
-
-
-
-
-
-
-
Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering
-
-
-
-
-
-
-
Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026
-
-
-
-
-
-
-
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025
-
-
-
-
-
-
-
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program
-
-
-
-
-
-
-
Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

